About SomaSignal™ Tests
By measuring thousands of proteins at a time with the SomaScan® Platform, we can uncover specific patterns of protein changes that provide information on current status and future trajectory for virtually every disease or condition of interest from one blood sample.
Each protein pattern becomes the basis of a specific “SomaSignal test” that can be ordered by doctors to help them manage their patients’ health more completely and effectively.
Want more information about our SomaSignal tests?
Current SomaSignal Tests in Clinical Use
The first seven SomaSignal tests were made available to ordering physicians in a limited number of clinical practices in the Denver, Colorado area in September 2019. The next three tests (Glucose Tolerance, Visceral Fat and Resting Energy Rate) became available in January 2020. We are working closely with these physicians to maximize the benefit of these tests to their patients. Please contact us for more information.
Current SomaSignal Tests for Research Use Only
The SomaSignal™ non-alcoholic steatohepatitis (NASH) Bundle provides information related to the same components seen in a liver biopsy — steatosis, lobular inflammation, hepatocellular ballooning and fibrosis — without the need for a liver biopsy.
The SomaSignal™ NASH Bundle tests are for Research Use Only and can be used to better understand the biology of nonalcoholic fatty liver disease (NAFLD) and NASH, including identifying new drug targets and drug effects.
For more information on the SomaSignal™ NASH Bundle, click here
All SomaSignal test results are derived from the SomaScan Platform, which is deployed in an accredited laboratory at SomaLogic’s headquarters in Boulder, Colorado. The SomaScan Assay and SomaSignal test reports are currently available for Research Use Only worldwide, for Investigational Use Only in certain geographies, and for Commercial Use through a limited number of authorized providers. The SomaSignal tests are developed and their performance characteristics determined by SomaLogic, Inc. They have not been cleared or approved by the US Food and Drug Administration.